Search

Your search keyword '"Sayer, Gabriel"' showing total 1,141 results
Start Over Author "Sayer, Gabriel"
1,141 results on '"Sayer, Gabriel"'

2. Added prognostic value of visually estimated coronary artery calcium among heart transplant recipients

Author

Clerkin, Kevin J., Sewanan, Lorenzo, Griffin, Jan M., DeFilippis, Ersilia M., Peng, Boyu, Chernovolenko, Margarita, Harris, Erin, Prasad, Nikil, Colombo, Paolo C., Yuzefpolskaya, Melana, Fried, Justin, Raikhelkar, Jayant, Topkara, Veli K., Castillo, Michelle, Lam, Elaine Y., Latif, Farhana, Takeda, Koji, Uriel, Nir, Sayer, Gabriel, and Einstein, Andrew J.

Published
2024
Full Text
View/download PDF

5. REPAIRS Delphi: A UK and Ireland Consensus Statement on the Management of Infected Arterial Pseudoaneurysms Secondary to Groin Injecting Drug Use

Author

Munro, Euan N., Flett, Murray M., Hussey, Keith, Wolf, Bernhard, Jamieson, Russell W., Wallace, David, Vesey, Alex T., McCaslin, James, Wong, Peng, Tenna, Adriano, Badger, Stephen, Harrison, Gareth, Ghosh, Jon, Al-Khaffaf, Haytham, Torella, Francesco, McBride, Richard, Drinkwater, Susan, Antoniou, George A., Bhasin, Neeraj, Pradhan, Aniket, Smith, George, Coughlin, Patrick, Brar, Ranjeet, Elsherif, Mohamed, Lau, Simon, Peach, George, Kulkarni, Sachin, Brooks, Marcus, Wijesinghe, Lasantha, McCune, Ken, Hopper, Neil, Cowan, Andrew, Hunter, Ian, Mittapalli, Devender, Garnham, Andrew, Jones, Steven, Rajagopalan, Sriram, Tiwari, Alok, Imray, Chris, Atwal, Amarjit, Bahia, Sandeep, Jones, Keith G., Handa, Ashok, Bowbrick, Ginny, Nordon, Ian, Button, Matthew, Rudarakanchana, Nung, D’Souza, Rovan, Tai, Nigel, Moxey, Paul, Bicknell, Colin, Gibbs, Richard, Zayed, Hany, Saratzis, Athanasios, Kannan, Ramesh, Batchelder, Andrew, Chong, Peter Lee, Rowlands, Timothy, Hildebrand, Diane, Thapar, Ankur, Chaudhuri, Arindam, Howard, Adam, Metcalfe, Matthew, Al-Jundi, Wissam, Sayer, Gabriel, Lewis, David, Sohrabi, Soroush, Woolgar, Justin, Fligelstone, Louis, Davies, Huw, Hill, Susan, Fulton, Greg, Moneley, Daragh, McDonnell, Ciaran, Martin, Zenia, Dowdall, Joseph, Tierney, Sean, Walsh, Stewart, Medani, Mekki, Gosi, Gergely, MacLeod, Caitlin S., Nagy, John, Radley, Andrew, Khan, Faisel, Rae, Nikolas, Wilson, Michael S.J., and Suttie, Stuart A.

Published
2024
Full Text
View/download PDF

6. Alterations in the sarcopenia index are associated with inflammation, gut, and oral microbiota among heart failure, left ventricular assist device, and heart transplant patients

Author

Yuzefpolskaya, Melana, Bohn, Bruno, Ladanyi, Annamaria, Pinsino, Alberto, Braghieri, Lorenzo, Carey, Matthew R., Clerkin, Kevin, Sayer, Gabriel T., Latif, Farhana, Koji, Takeda, Uriel, Nir, Nandakumar, Renu, Uhlemann, Anne-Catrin, Colombo, Paolo C., and Demmer, Ryan T.

Published
2024
Full Text
View/download PDF

28. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update

Author

Saeed, Diyar, Feldman, David, Banayosy, Aly El, Birks, Emma, Blume, Elizabeth, Cowger, Jennifer, Hayward, Christopher, Jorde, Ulrich, Kremer, Jamila, MacGowan, Guy, Maltais, Simon, Maybaum, Simon, Mehra, Mandeep, Shah, Keyur B., Mohacsi, Paul, Schweiger, Martin, Schroeder, Sarah E., Shah, Palak, Slepian, Marvin, Tops, Laurens F., Alvarez, Paulino, Arabia, Francisco, Aslam, Saima, Benson-Louis, Louis, IV, Birati, Edo, Buchholz, Holger W., Cedars, Ari, Christensen, Dawn, Ciarka, Agnieszka, Coglianese, Erin, Cogswell, Rebecca, Cook, Jennifer, Copeland, Jack, Costello, Jose Gonzalez, Drakos, Stavros G, Eghtesady, Pirooz, Elliot, Tonya, Estep, Jerry D., Eulert-Grehn, Jaime-Juergen, Fabrizio, De Rita, Garbade, Jens, Gelow, Jill, Guglin, Maya, Hernandez-Montfort, Jaime, Horstmanshof, Doug, John, Ranjit, Kanwar, Manreet, Khaliel, Feras, Kim, Gene, Kumar, Sachin, Lavee, Jacob, Leache, Marzia, Leprince, Pascal, Lim, Sern, Loforte, Antonio, Maly, Jiri, Najjar, Samer, Netuka, Ivan, Pamboukian, Salpy V., Patel, Snehal R, Pinney, Sean, Pluym, Christina Vander, Potapov, Evgenij, Robson, Desiree, Rochlani, Yogita, Russell, Stuart, Sandau, Kristin, Sandoval, Elena, Sayer, Gabriel, Schettle, Sarah, Schibilsky, David, Schlöglhofer, Thomas, Schmitto, Jan, Siddique, Aleem, Silvestry, Scott, Slaughter, Mark S, Sun, Benjamin, Takayama, Hiroo, Tedford, Ryan, Teuteberg, Jeffrey J., Ton, Van-Khue, Uriel, Nir, Vierecke, Juliane, Zimpfer, Daniel, and D'Alessandro, David

Published
2023
Full Text
View/download PDF

30. Estimation of Central Venous Pressure by Pacemaker Lead Impedances in Left Ventricular Assist Device Patients.

Author

Imamura, Teruhiko, Moss, Joshua D, Flatley, Erin, Rodgers, Daniel, Kim, Gene, Raikhelkar, Jayant, Sarswat, Nitasha, Kalantari, Sara, Nguyen, Ann, Juricek, Colleen, Burkhoff, Daniel, Song, Tae, Ota, Takeyoshi, Jeevanandam, Valluvan, Sayer, Gabriel, and Uriel, Nir

Subjects
Engineering, Biomedical Engineering, Heart Disease, Bioengineering, Clinical Research, Cardiovascular, Aged, Central Venous Pressure, Cohort Studies, Electric Impedance, Female, Heart Failure, Heart Ventricles, Heart-Assist Devices, Hemodynamics, Humans, Male, Mathematical Concepts, Middle Aged, Pacemaker, Artificial, Biomedical engineering
Abstract

Volume status assessment in left ventricular assist device (LVAD) patients remains challenging. Cardiac resynchronization therapy (CRT) devices are common in LVAD patients, and the impedance across the CRT leads may be associated with hemodynamics and serve as a tool for noninvasive estimation of volume status. Ninety-one sets of measurements including cardiac filling pressures and lead impedances were prospectively obtained during ramp tests from 11 LVAD patients (65.5 ± 9.7 years old; nine male) with CRT devices. Right atrial (RA), right ventricular (RV), and left ventricular (LV) lead impedances were all significantly associated with central venous pressure (CVP) (p < 0.05). We derived the following equation: estimated CVP = 47.90-(0.086 × RA lead impedance) + (0.013 × RV lead impedance)-(0.020 × LV lead impedance). The estimated CVP had a significant correlation (r = 0.795) and good agreement with the measured CVP (mean difference -0.14 ± 1.77 mmHg). Applying the above equation on the validation cohort of twenty-one patients also maintained a strong association with measured CVP (r = 0.705). In conclusion, we have derived a novel equation to estimate CVP using lead impedance measurements. This finding may allow noninvasive monitoring of volume status in LVAD patients.

Published
2020

46. CAV Trajectories Among Patients With No or Mild CAV at 10 Years Posttransplant.

Author

Harris, Erin, Prasad, Nikil, Skoll, Devin, Kumar, Sambhavi Sneha, Fried, Justin, Topkara, Veli, Raikhelkar, Jayant K., DeFilippis, Ersilia M., Latif, Farhana, Yuzefpolskaya, Melana, Colombo, Paolo C., Uriel, Nir, Takeda, Koji, Sayer, Gabriel T., and Clerkin, Kevin J.

Subjects
HEART transplantation, CORONARY artery disease, CARDIOVASCULAR diseases, VASCULAR diseases, ANGIOGRAPHY
Abstract

Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Prior studies identified distinct CAV trajectories in the early post‐HT period with unique predictors, but the evolution of CAV in later periods is not well‐described. This study assessed the prevalence of late CAV progression and associated risk factors in HT recipients with ISHLT CAV 0/1 at 10 years post‐HT. Consecutive adult patients who underwent HT from January 2000 to December 2008 were evaluated and grouped by CAV trajectories into progressors (developed ISHLT CAV 2/3) or nonprogressors (remained ISHLT CAV 0/1). A total of 130 patients were included with a median age at angiography of 61.7 years and a median follow‐up time of 4.8 years. 8.5% progressed to CAV 2/3, while the remaining 91.5% were nonprogressors. Progression was not associated with death or retransplantation (27.3% [progressor] vs. 21.0% [nonprogressor], p = 0.70). These data may inform shared decision‐making about late CAV screening. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Durable left ventricular assist devices as a bridge to transplantation: what to expect along the way?

Author

Fernandez Valledor, Andrea, Moeller, Cathrine M., Rubinstein, Gal, Oren, Daniel, Rahman, Salwa, Baranowska, Julia, Lee, Changhee, Lorenzatti, Daniel, Righini, Francesca Maria, Lotan, Dor, Sayer, Gabriel T., and Uriel, Nir

Subjects
HEART assist devices, TRANSPLANTATION of organs, tissues, etc., EMBRYO implantation, TREATMENT effectiveness, PATIENT selection
Abstract

Introduction: The scarcity of donors coupled with the improvements in left ventricular assist devices (LVAD) technology has led to the use of LVAD as a bridge to transplantation (BTT). Areas covered: The authors provide an overview of the current status of LVAD BTT implantation with special focus ranging from patient selection and pre-implantation optimization to post-transplant outcomes. Expert Opinion: The United Network for Organ Sharing 2018 policy amendment resulted in a significant reduction in the number of LVADs used for BTT in the US. To overcome this issue, modifications in the US allocation policy to consider factors such as days on device support, age, and type of complications may be necessary to potentially increase implantation rates. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Unplanned hospital readmissions following HeartMate 3 implantation: Readmission rates, causes, and impact on survival.

Author

Shih, Hueyjong, Mondellini, Giulio M., Kurlansky, Paul A., Sun, Jocelyn, Ning, Yuming, Feldman, Vivian R., Tiburcio, Melie, Maguire, Conor W., Ladanyi, Annamaria, Clerkin, Kevin, Naka, Yoshifumi, Sayer, Gabriel T., Uriel, Nir, Colombo, Paolo C., Takeda, Koji, and Yuzefpolskaya, Melana

Subjects
HEART assist devices, PATIENT readmissions, ACADEMIC medical centers, QUALITY of life, OVERALL survival
Abstract

Background: Hospital readmissions following left ventricular assist device (LVAD) remain a frequent comorbidity, associated with decreased quality of life and increased resources utilization. This study sought to determine causes, predictors, and impact on survival of hospitalizations during HeartMate 3 (HM3) support. Methods: All patients implanted with HM3 between November 2014 to December 2019 at Columbia University Irving Medical Center were consecutively enrolled in the study. Demographics and clinical characteristics from the index admission and the first outpatient visit were collected and used to estimate 1‐year and 900‐day readmission‐free survival and overall survival. Multivariable analysis was performed for subsequent readmissions. Results: Of 182 patients who received a HM3 LVAD, 167 (92%) were discharged after index admission and experienced 407 unplanned readmissions over the median follow up of 727 (interquartile range (IQR): 410.5, 1124.5) days. One‐year and 900‐day mean cumulative number of all‐cause unplanned readmissions was 0.43 (95%CI, 0.36, 0.51) and 1.13 (95%CI, 0.99, 1.29). The most frequent causes of rehospitalizations included major infections (29.3%), bleeding (13.2%), device‐related (12.5%), volume overload (7.1%), and other (28%). One‐year and 900‐day survival free from all‐cause readmission was 38% (95%CI, 31–46%) and 16.6% (95%CI, 10.3–24.4%). One‐year and 900‐day freedom from 2, 3, and ≥4 readmissions were 60.7%, 74%, 74.5% and 26.2%, 33.3%, 41.3%. One‐year and 900‐day survival were unaffected by the number of readmissions and remained >90%. Male sex, ischemic etiology, diabetes, lower serum creatinine, longer duration of index hospitalization, and a history of readmission between discharge and the first outpatient visit were associated with subsequent readmissions. Conclusions: Unplanned hospital readmissions after HM3 are common, with infections and bleeding accounting for the majority of readmissions. Irrespective of the number of readmissions, one‐year survival remained unaffected. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results